Zhilin Zeng1, Juan Zhan2, Kaimin Zhang3, Huilong Chen4, Sheng Cheng5. 1. Department of Infectious Diseases, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan, 430030, China. 2. Department of Dermatology, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. 3. Department of Medical Engineering, Guangdong Provincial People's Hospital, Guangzhou, China. 4. Department of Infectious Diseases, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, No. 1095, Jiefang Avenue, Wuhan, 430030, China. huilong_chen@126.com. 5. Department of Respiratory Diseases, University-Town Hospital of Chongqing Medical University, Chongqing, China.
Abstract
PURPOSE: We aimed to estimate the burden of UTIs by age, sex, and socioeconomic status in 204 countries and territories from 1990 to 2019. METHODS: We used data from Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to analyse the incidence, mortality, and disability-adjusted life-years (DALYs) due to UTIs at the global, regional, and national levels. Estimates are presented as numbers and age-standardised or age-specific rates per 100,000 population, with 95% uncertainty intervals (UIs). We further explored the associations between the incidence, mortality, DALYs, and socio-demographic index (SDI) as a proxy for the development status of regions and countries. RESULTS: In 2019, more than 404.6 million (95% UI 359.4-446.5) individuals had UTIs globally and nearly 236,786 people (198,433-259,034) died of UTIs, contributing to 5.2 million (4.5-5.7) DALYs. The age-standardised incidence rate increased from 4715.0 (4174.2-5220.6) per 100,000 population in 1990 to 5229.3 (4645.3-5771.2) per 100,000 population in 2019. At the GBD regional level, the highest age-standardised incidence rate in 2019 occurred in Tropical Latin America (13,852.9 [12,135.6-15,480.3] per 100,000 population). At the national level, Ecuador had the highest age-standardised incidence rate (15,511.3 [13,685.0-17,375.6] per 100,000 population). The age-standardised death rates were highest in Barbados (19.5 [13.7-23.5] per 100,000 population). In addition, age-standardised incidence, death, and DALY rates generally increased across the SDI. CONCLUSIONS: Our study results suggest a globally rising trend of UTI burden between 1990 and 2019.
PURPOSE: We aimed to estimate the burden of UTIs by age, sex, and socioeconomic status in 204 countries and territories from 1990 to 2019. METHODS: We used data from Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to analyse the incidence, mortality, and disability-adjusted life-years (DALYs) due to UTIs at the global, regional, and national levels. Estimates are presented as numbers and age-standardised or age-specific rates per 100,000 population, with 95% uncertainty intervals (UIs). We further explored the associations between the incidence, mortality, DALYs, and socio-demographic index (SDI) as a proxy for the development status of regions and countries. RESULTS: In 2019, more than 404.6 million (95% UI 359.4-446.5) individuals had UTIs globally and nearly 236,786 people (198,433-259,034) died of UTIs, contributing to 5.2 million (4.5-5.7) DALYs. The age-standardised incidence rate increased from 4715.0 (4174.2-5220.6) per 100,000 population in 1990 to 5229.3 (4645.3-5771.2) per 100,000 population in 2019. At the GBD regional level, the highest age-standardised incidence rate in 2019 occurred in Tropical Latin America (13,852.9 [12,135.6-15,480.3] per 100,000 population). At the national level, Ecuador had the highest age-standardised incidence rate (15,511.3 [13,685.0-17,375.6] per 100,000 population). The age-standardised death rates were highest in Barbados (19.5 [13.7-23.5] per 100,000 population). In addition, age-standardised incidence, death, and DALY rates generally increased across the SDI. CONCLUSIONS: Our study results suggest a globally rising trend of UTI burden between 1990 and 2019.
Authors: Florian Wagenlehner; Björn Wullt; Stefania Ballarini; Daniel Zingg; Kurt G Naber Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2017-07-31 Impact factor: 2.217
Authors: F L Ruben; S R Dearwater; C W Norden; L H Kuller; K Gartner; A Shalley; G Warshafsky; S F Kelsey; C O'Donnell; E Means Journal: Am J Epidemiol Date: 1995-01-15 Impact factor: 4.897
Authors: James A Johnson; Lydia F Delaney; Vaishali Ojha; Medha Rudraraju; Kaylie R Hintze; Nazema Y Siddiqui; Tatyana A Sysoeva Journal: Front Cell Infect Microbiol Date: 2022-06-23 Impact factor: 6.073
Authors: Mohammad Aminul Islam; Md Rayhanul Islam; Rizwana Khan; Mohammed Badrul Amin; Mahdia Rahman; Muhammed Iqbal Hossain; Dilruba Ahmed; Muhammad Asaduzzaman; Lee W Riley Journal: PLoS One Date: 2022-09-15 Impact factor: 3.752